Previous close | 48.07 |
Open | 47.78 |
Bid | 41.00 x 900 |
Ask | 46.92 x 800 |
Day's range | 45.78 - 47.78 |
52-week range | 21.06 - 66.47 |
Volume | |
Avg. volume | 501,950 |
Market cap | 2.474B |
Beta (5Y monthly) | 0.41 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.